Department of Surgery, Saitama Medical Center, Jichi Medical University, Japan.
Clin Colorectal Cancer. 2010 Jan;9(1):48-51. doi: 10.3816/CCC.2010.n.006.
The aim of this study was to evaluate the contribution of each examination included in the postoperative surveillance program, especially that of serum tumor markers.
Patients who underwent curative surgery for colorectal carcinoma (CRC) from January 2000 to December 2006 were enrolled. The postoperative surveillance program in our department includes tumor marker (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA] 19-9) measurement every 3 months for 5 years, chest radiograph or chest computed tomography (CT) every 3 months for 2 years and then every 6 months until 5 years, and abdominal CT every 3 months for 2 years and then every 6 months until 5 years. The first examination that revealed abnormality in patients who developed recurrence was analyzed.
During the study period, 105 recurrences were diagnosed. There were 45 hepatic recurrences, 23 local recurrences, 20 pulmonary recurrences, 16 lymph node recurrences, and 10 peritoneal recurrences. Computed tomography, CEA, and CA 19-9 were the first abnormal examination(s) in 77, 23, and 26 patients, respectively. Tumor markers detected the recurrence earlier than did CT in 27% of patients. CEA and CA 19-9 equally contributed to detection with respect to the number of patients, while the sites of detected recurrences differed.
For early detection of occult recurrence of CRC, CT was the most reliable modality. On the other hand, tumor markers were also relevant. Given the recent advances in multimodal approaches for advanced CRC, the combination of CT, CEA, and CA 19-9, which is currently not included in guidelines, should be routinely performed.
本研究旨在评估术后监测方案中每项检查的贡献,尤其是血清肿瘤标志物的贡献。
我们纳入了 2000 年 1 月至 2006 年 12 月期间接受结直肠癌(CRC)根治性手术的患者。我们科室的术后监测方案包括每隔 3 个月检测肿瘤标志物(癌胚抗原[CEA]和糖链抗原[CA]19-9),连续 5 年;每隔 3 个月进行胸部 X 线或胸部计算机断层扫描(CT),连续 2 年,然后每 6 个月至 5 年;每隔 3 个月进行腹部 CT,连续 2 年,然后每 6 个月至 5 年。对出现复发的患者中首次发现异常的检查进行了分析。
在研究期间,诊断出 105 例复发。其中 45 例肝转移,23 例局部复发,20 例肺转移,16 例淋巴结转移,10 例腹膜转移。CT、CEA 和 CA 19-9 分别在 77、23 和 26 例患者中首次发现异常。在 27%的患者中,肿瘤标志物比 CT 更早检测到复发。CEA 和 CA 19-9 在检测到的患者数量上具有同等的作用,但检测到的复发部位不同。
对于 CRC 隐匿性复发的早期检测,CT 是最可靠的方法。另一方面,肿瘤标志物也很重要。鉴于目前对晚期 CRC 采用的多模态方法的进展,应常规进行目前未包含在指南中的 CT、CEA 和 CA 19-9 联合检测。